

Press Release

ProStrakan Group plc

Director / PDMR Shareholding

Galashiels, UK. 21 September 2010 – ProStrakan Group plc (“the Company”), the international specialty pharmaceutical business, today announces that on 20 September it made a grant of an option over 1,000,000 of the Company’s ordinary shares to Peter Allen, Acting Chief Executive and Chairman of the Company’s Board of Directors. The option was granted at an exercise price of 46.5 pence per share.

The option was granted pursuant to Listing Rule 9.4.2(2) and made under an agreement entered into in connection with the appointment of Peter Allen, who has been Non-Executive Chairman since December 2007, as Acting Chief Executive of the Company. The option granted will be subject to the Company achieving certain performance criteria over a three year performance period that commenced on 20 September 2010. No consideration was paid for the grant of the option. This notification is made pursuant to DTR 3.1.4(1)(a).

Andrew McLean
Company Secretary

Ends

For further enquiries, please contact:

ProStrakan	+44 (0) 1896 664000
Callum Spreng, Corporate Communications	
Brunswick Group	+44 (0) 20 7404 5959
Jon Coles / Justine McIlroy	

About ProStrakan:

ProStrakan Group plc is a rapidly growing specialty pharmaceutical company engaged in the development and commercialisation of prescription medicines for the treatment of unmet therapeutic needs in major markets.

ProStrakan's head office is located in Galashiels in Scotland. The company's development capabilities are centered in Galashiels and Bedminster, New Jersey, USA. Sales and marketing of ProStrakan's portfolio of products are handled by commercial subsidiaries in the UK, US, France, Germany, Spain, Italy and other EU countries.

You can learn more about the business at: www.prostrakan.com